Conyers Investments LLC filed a Form 4 with the SEC on September 3, 2026, disclosing the acquisition of 49,600 shares of Newsmax Inc. Class B Common Stock on that same date.
Jolanda Howe, Senior Vice President and Global Controller of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), filed a Form 4 on September 3, 2026, reporting the sale of 658 shares of common stock on September 2, 2026.
Chantelle Yvette Breithaupt, Senior Vice President and Chief Financial Officer of Arista Networks, Inc. (NYSE:ANET), filed a statement of changes in beneficial ownership on September 3, 2026, reporting the sale of 612 shares of common stock on September 1, 2026.
Josh Silverman, Executive Chair of the Board of Etsy Inc. (NASDAQ:ETSY), filed a Form 4 on September 3, 2026, reporting option exercises and open-market sales of common stock on September 1 and September 3, 2026, pursuant to a Rule 10b5-1 trading plan.
Richard Edward Colburn III, Chief Product & Technology Officer at Etsy Inc. (NASDAQ:ETSY), filed a Form 4 on September 3, 2026, disclosing restricted stock unit vesting and multiple open-market stock sales that occurred on September 1 and September 3, 2026.
A Form 4 filed with the SEC on September 3, 2026 discloses that Frederick R. Wilson, a director of Etsy Inc (NYSE:ETSY), sold a total of 20,000 shares of Etsy common stock on September 1, 2026 under a pre-established Rule 10b5-1 trading plan.
Douglas J. Herrington, CEO Worldwide Amazon Stores at Amazon.com Inc., filed a Form 4 on September 3, 2026, reporting the sale of 1,000 shares of Amazon common stock on September 1, 2026.
Director Robert M. Eversole filed a Form 4 with the SEC on September 3, 2026, disclosing a transfer of 2,386 shares of Advanced Drainage Systems, Inc. common stock to a revocable trust on September 1, 2026.
Patrick M. Coyle, Jr., Executive Vice President of Supply Chain Management at Advanced Drainage Systems, Inc., filed a Form 4 on September 3, 2026, reporting a tax-withholding transaction in Common Stock dated September 1, 2026.
Courtney Phillips, General Counsel and Corporate Secretary of Maze Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 3, 2026, reporting a restricted stock unit settlement transaction dated September 1, 2026.